Glycosade ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	1
256	Muscle glycogenosis	1
257	Hepatic glycogenosis	2

65. Primary immunodeficiency

Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02054832 (ClinicalTrials.gov)	November 2013	31/1/2014	Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch	A Comparison of Quality of Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard and Modified Uncooked Cornstarch	Glycogen Storage Disease Type IA;Glycogen Storage Disease Type IB;Glycogen Storage Disease Type III;Glycogen Storage Disease Type 0	Dietary Supplement: Glycosade	John Mitchell	NULL	Completed	2 Years	50 Years	Both	11	N/A	Canada

Clinical trials : 180 / Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02054832 (ClinicalTrials.gov)	November 2013	31/1/2014	Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch	A Comparison of Quality of Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard and Modified Uncooked Cornstarch	Glycogen Storage Disease Type IA;Glycogen Storage Disease Type IB;Glycogen Storage Disease Type III;Glycogen Storage Disease Type 0	Dietary Supplement: Glycosade	John Mitchell	NULL	Completed	2 Years	50 Years	Both	11	N/A	Canada

Clinical trials : 14 / Drugs : 27 - (DrugBank : 7) / Drug target genes : 3 - Drug target pathways : 8

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02176096 (ClinicalTrials.gov)	July 2014	24/6/2014	Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial	Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial	Glycogen Storage Disorder Type 1;Hypoglycemia;Cornstarch;Glycosade	Dietary Supplement: Glycosade	University of Manitoba	Co-Investigator - Dr. Cheryl Rockman-Greenberg	Completed	5 Years	18 Years	All	4	N/A	Canada
2	NCT02054832 (ClinicalTrials.gov)	November 2013	31/1/2014	Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch	A Comparison of Quality of Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard and Modified Uncooked Cornstarch	Glycogen Storage Disease Type IA;Glycogen Storage Disease Type IB;Glycogen Storage Disease Type III;Glycogen Storage Disease Type 0	Dietary Supplement: Glycosade	John Mitchell	NULL	Completed	2 Years	50 Years	Both	11	N/A	Canada